|  | Cancer (N=6145) | Non-Cancer (N=52843) | Overall (N=58988) |
| --- | --- | --- | --- |
| **In-hospital Mortality** |  |  |  |
| Died | 1,864 (30.3%) | 7,656 (14.5%) | 9,520 (16.1%) |
| Survived | 4,281 (69.7%) | 45,187 (85.5%) | 49,468 (83.9%) |
| **Length of stay if died (days)** |  |  |  |
| Mean (SD) | 6.61 (7.41) | 8.16 (13.0) | 7.86 (12.1) |
| Median (Q2, Q3) | 4.13 (4.13, 8.13) | 5.17 (5.17, 10.3) | 4.96 (4.96, 9.84) |
| **Length of stay if survived (days)** |  |  |  |
| Mean (SD) | 6.93 (8.03) | 7.98 (9.77) | 7.89 (9.64) |
| Median (Q2, Q3) | 4.21 (4.21, 8.41) | 5.46 (5.46, 9.84) | 5.33 (5.33, 9.75) |
| **Mechanic Ventilation** |  |  |  |
| Received | 2,446 (39.8%) | 25,480 (48.2%) | 27,926 (47.3%) |
| Not received | 3,699 (60.2%) | 27,363 (51.8%) | 31,062 (52.7%) |
| **Renal Replacement Therapy** |  |  |  |
| Received | 351 (5.7%) | 4,094 (7.7%) | 4,445 (7.5%) |
| Did not receive | 5,794 (94.3%) | 48,749 (92.3%) | 54,543 (92.5%) |
| **Vasopressor(s)** |  |  |  |
| Received | 2,530 (41.2%) | 22,591 (42.8%) | 25,121 (42.6%) |
| Not received | 3,615 (58.8%) | 30,252 (57.2%) | 33,867 (57.4%) |
| **Database** |  |  |  |
| MIMIC | 3,875 (63.1%) | 19,744 (37.4%) | 23,619 (40.0%) |
| eICU | 2,270 (36.9%) | 33,099 (62.6%) | 35,369 (60.0%) |
| **Age by group (years)** |  |  |  |
| 18 - 44 | 341 (5.5%) | 6,278 (11.9%) | 6,619 (11.2%) |
| 45 - 64 | 2,210 (36.0%) | 17,508 (33.1%) | 19,718 (33.4%) |
| 65 - 74 | 1,745 (28.4%) | 12,102 (22.9%) | 13,847 (23.5%) |
| 75 - 84 | 1,354 (22.0%) | 10,688 (20.2%) | 12,042 (20.4%) |
| 85 and higher | 495 (8.1%) | 6,267 (11.9%) | 6,762 (11.5%) |
| **Age overall (years)** |  |  |  |
| Mean (SD) | 66.8 (13.2) | 65.0 (16.6) | 65.2 (16.3) |
| Median (Q2, Q3) | 67.0 (67.0, 76.0) | 67.0 (67.0, 78.0) | 67.0 (67.0, 78.0) |
| **Sex** |  |  |  |
| Female | 2,517 (41.0%) | 24,389 (46.2%) | 26,906 (45.6%) |
| Male | 3,628 (59.0%) | 28,454 (53.8%) | 32,082 (54.4%) |
| **Race** |  |  |  |
| Asian | 198 (3.2%) | 942 (1.8%) | 1,140 (1.9%) |
| Black | 581 (9.5%) | 5,355 (10.1%) | 5,936 (10.1%) |
| Hispanic | 262 (4.3%) | 2,210 (4.2%) | 2,472 (4.2%) |
| Other | 559 (9.1%) | 5,444 (10.3%) | 6,003 (10.2%) |
| White | 4,545 (74.0%) | 38,892 (73.6%) | 43,437 (73.6%) |
| **SOFA continuous** |  |  |  |
| Mean (SD) | 5.57 (3.48) | 5.11 (3.27) | 5.16 (3.29) |
| Median (Q2, Q3) | 5.00 (5.00, 7.00) | 5.00 (5.00, 7.00) | 5.00 (5.00, 7.00) |
| **Charlson Comorbidity Index** |  |  |  |
| Mean (SD) | 7.97 (3.31) | 4.66 (2.79) | 5.00 (3.03) |
| Median (Q2, Q3) | 8.00 (8.00, 10.0) | 5.00 (5.00, 6.00) | 5.00 (5.00, 7.00) |
| **Full Code upon Admission** |  |  |  |
| Not Full Code | 609 (9.9%) | 3,948 (7.5%) | 4,557 (7.7%) |
| Full Code | 5,536 (90.1%) | 48,895 (92.5%) | 54,431 (92.3%) |
| **Full Code upon Discharge** |  |  |  |
| Not Full Code | 1,309 (21.3%) | 9,316 (17.6%) | 10,625 (18.0%) |
| Full Code | 4,836 (78.7%) | 43,527 (82.4%) | 48,363 (82.0%) |
| **Hypertension** |  |  |  |
| Hypertension absent | 2,540 (41.3%) | 20,782 (39.3%) | 23,322 (39.5%) |
| Hypertension present | 3,605 (58.7%) | 32,061 (60.7%) | 35,666 (60.5%) |
| **Heart Failure** |  |  |  |
| CHF absent | 4,702 (76.5%) | 37,738 (71.4%) | 42,440 (71.9%) |
| CHF present | 1,443 (23.5%) | 15,105 (28.6%) | 16,548 (28.1%) |
| **Asthma** |  |  |  |
| Asthma absent | 5,965 (97.1%) | 49,659 (94.0%) | 55,624 (94.3%) |
| Asthma present | 180 (2.9%) | 3,184 (6.0%) | 3,364 (5.7%) |
| **COPD** |  |  |  |
| COPD absent | 4,610 (75.0%) | 39,989 (75.7%) | 44,599 (75.6%) |
| COPD present | 1,535 (25.0%) | 12,854 (24.3%) | 14,389 (24.4%) |
| **CKD** |  |  |  |
| CKD Absent | 5,581 (90.8%) | 46,544 (88.1%) | 52,125 (88.4%) |
| CKD Present | 564 (9.2%) | 6,299 (11.9%) | 6,863 (11.6%) |
| **Solid Cancer** |  |  |  |
| Not Present | 3,347 (54.5%) | 52,843 (100%) | 56,190 (95.3%) |
| Present | 2,798 (45.5%) | 0 (0%) | 2,798 (4.7%) |
| **Hematological Cancer** |  |  |  |
| Not Present | 4,718 (76.8%) | 52,843 (100%) | 57,561 (97.6%) |
| Present | 1,427 (23.2%) | 0 (0%) | 1,427 (2.4%) |
| **Metastasized Cancer** |  |  |  |
| Not Present | 4,225 (68.8%) | 52,843 (100%) | 57,068 (96.7%) |
| Present | 1,920 (31.2%) | 0 (0%) | 1,920 (3.3%) |
| **Colon and Rectal (combined)** |  |  |  |
| Not Present | 5,715 (93.0%) | 52,843 (100%) | 58,558 (99.3%) |
| Present | 430 (7.0%) | 0 (0%) | 430 (0.7%) |
| **Liver and intrahepatic BD** |  |  |  |
| Not Present | 5,783 (94.1%) | 52,843 (100%) | 58,626 (99.4%) |
| Present | 362 (5.9%) | 0 (0%) | 362 (0.6%) |
| **Pancreatic** |  |  |  |
| Not Present | 5,842 (95.1%) | 52,843 (100%) | 58,685 (99.5%) |
| Present | 303 (4.9%) | 0 (0%) | 303 (0.5%) |
| **Lung (including bronchus)** |  |  |  |
| Not Present | 5,006 (81.5%) | 52,843 (100%) | 57,849 (98.1%) |
| Present | 1,139 (18.5%) | 0 (0%) | 1,139 (1.9%) |
| **Melanoma** |  |  |  |
| Not Present | 6,090 (99.1%) | 52,843 (100%) | 58,933 (99.9%) |
| Present | 55 (0.9%) | 0 (0%) | 55 (0.1%) |
| **Breast** |  |  |  |
| Not Present | 5,970 (97.2%) | 52,843 (100%) | 58,813 (99.7%) |
| Present | 175 (2.8%) | 0 (0%) | 175 (0.3%) |
| **Endometrial** |  |  |  |
| Not Present | 6,041 (98.3%) | 52,843 (100%) | 58,884 (99.8%) |
| Present | 104 (1.7%) | 0 (0%) | 104 (0.2%) |
| **Prostate** |  |  |  |
| Not Present | 5,812 (94.6%) | 52,843 (100%) | 58,655 (99.4%) |
| Present | 333 (5.4%) | 0 (0%) | 333 (0.6%) |
| **Kidney** |  |  |  |
| Not Present | 5,984 (97.4%) | 52,843 (100%) | 58,827 (99.7%) |
| Present | 161 (2.6%) | 0 (0%) | 161 (0.3%) |
| **Bladder** |  |  |  |
| Not Present | 5,970 (97.2%) | 52,843 (100%) | 58,813 (99.7%) |
| Present | 175 (2.8%) | 0 (0%) | 175 (0.3%) |
| **Thyroid** |  |  |  |
| Not Present | 6,118 (99.6%) | 52,843 (100%) | 58,961 (100.0%) |
| Present | 27 (0.4%) | 0 (0%) | 27 (0.0%) |
| **NHL** |  |  |  |
| Not Present | 5,653 (92.0%) | 52,843 (100%) | 58,496 (99.2%) |
| Present | 492 (8.0%) | 0 (0%) | 492 (0.8%) |
| **Leukemia** |  |  |  |
| Not Present | 5,525 (89.9%) | 52,843 (100%) | 58,368 (98.9%) |
| Present | 620 (10.1%) | 0 (0%) | 620 (1.1%) |